A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
The purpose of this study is to find out whether combining the study drugs rucaparib and nivolumab may be an effective treatment for advanced and/or metastatic LMS, and whether the study treatment works as well as the standard chemotherapy for this type of cancer.
Leiomyosarcoma
DRUG: Rucaparib|DRUG: Nivolumab
Best objective response rate, as assessed by RECIST 1.1, by 24 weeks
Progression free survival (PFS), PFS is defined as the period from start of study treatment until recurrent or progressive of disease (POD) is objectively documented (taking as reference for progressive disease the smallest measurement recorded on study), death, or date of last study visit involving assessment of disease status., at 24 weeks
The purpose of this study is to find out whether combining the study drugs rucaparib and nivolumab may be an effective treatment for advanced and/or metastatic LMS, and whether the study treatment works as well as the standard chemotherapy for this type of cancer.